Recruiting

AngelMed Guardian

Sponsor:

Angel Medical Systems

Code:

NCT05412927

Conditions

Acute Coronary Syndrome

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Interventions

PMA P150009 AngelMed Guardian® System

Study Details

Brief summary:

500 Patients (minimum) will be enrolled following commercial implant. Will be treated by their physicians using the standard of care.

Standard of care for the Guardian includes an in-office initial programming visit 7-14 days following implant and every 6 months.

Conditions

Acute Coronary Syndrome

Study ID

NCT05412927

Start date

Sep 7, 2022

Status verified date

Sep, 2025

Completion date

Dec, 2026

Anticipated

Primary completion date

Dec, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 21+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • 1\. Subject has at least one of the following conditions:

1. Diabetes (Type I or Type II)
2. Compromised renal function (Cr > 1.2 mg/dl or creatinine clearance less than 50)
3. TIMI Risk Score of at least 3

2\. Previously diagnosed with a high-risk acute coronary syndrome (e.g., Unstable Angina, STEMI or NSTEMI) or has undergone or is scheduled for CABG within 6 months of implantation.

3\. Has already undergone coronary angiography and revascularization, unless the physician determines it is appropriate to implant before or during the planned procedure.

4\. Lives in a geographic area in close proximity (within approximately 60 minutes by EMS) to any hospital that can treat AMI.

5\. Subjects (men or women) at least 21 years of age. Women of childbearing age must have a negative pregnancy test or confirmation of one of the following:

<!-- -->

1. Post-menopause or amenorrhoeic during the past year
2. Surgical sterilization
3. Use of effective contraceptive method

Exclusion Criteria:

  • 1\. In the investigator's opinion, subject lacks ability to respond appropriately to alarms, e.g., illiteracy, poor memory or cognitive function, dementia or other condition affecting memory function, etc.

2\. There is known compromised tissue at the site of lead implantation in the apex of the right ventricle, e.g., prior infarct affecting the RV apex location.

3\. A permanent pacemaker or ICD is already in place or the subject is indicated for ICD or pacemaker implantation based on the guidelines published by the American College of Cardiology as Class I and IIa recommendations. Class IIb recommendations are at the investigator's discretion.

4\. Subject cannot feel the IMD vibration when placed on top of the skin on the left pectoral side of the chest.

5\. Subject has recurrent or persistent atrial fibrillation. 6. Subject has recurrent or persistent non-sinus cardiac rhythm, second or third degree atrioventricular blocks, QRS duration greater than 120 ms, Benign Early Repolarization (BER), Brugada Syndrome (LLB, BBB, RBB) or Rate Induced BBB.

7\. Subject has left ventricular hypertrophy evidenced by EKG criteria. 8. Subject has any condition preventing the subcutaneous implantation of the Guardian® System in a left pectoral pouch, such as: superior vena cava thrombosis, subcutaneous tissue deemed inappropriate for the procedure or prior central venous access via portacath, Hickman, Groshong, or similar placed in a left pectoral location or left side PICC line.

9\. Subject has extremely heavy alcohol consumption (participates in binge drinking that leads to alcohol intoxication) or has history of alcohol or illicit drug abuse within past 5 years.

10\. There is evidence of unresolved infection (fever > 38o C and/or leukocytosis > 15,000).

11\. Subject has history of bleeding disorders or severe coagulopathy (platelets < 100,000 plts/ml; APTT or PT > 1.3 x reference range).

12\. Subject has had a hemorrhagic stroke or transient ischemic attack (TIA) in the past 6 months.

13\. Subject has a potentially fatal disease, such as cancer or refractory congestive heart failure, associated with limitation of life expectancy, which may lead to inadequate compliance to the protocol or confusing data interpretation.

14\. Subject has clinical conditions such as heart diseases, difficult-to-control blood pressure, difficult-to-control insulin-dependent diabetes or serious prior infections attributed to the diabetes, or others that, at the investigator's discretion, could seriously affect the subject's current clinical condition during study procedures.

15\. Subject has previously been implanted with an AngelMed Guardian® System, current participation or previous participation in another drug or device study in the past 30 days that conflicts with this study as determined by the study sponsor.

16\. Subject has experienced gastro-intestinal hemorrhage in the past 6 months. 17. Subject has any situation in which the use of aspirin is contraindicated for at least 6 months.

18\. Subject has epilepsy. 19. Subject has known severe allergies, e.g., peanut, bee sting, etc. 20. Subject has a known coronary occlusion that cannot be reperfused e.g. known multiple small vessel disease, saphenous vein graft, prior angiography where doctor could not intervene, or jailed occlusion.

Study Design

Enrollment

500 participants

Anticipated

Interventions and Outcome Measures

Arms

Patients who have had prior ACS events.

Patients who have had prior ACS events and who remain at high risk for recurrent ACS events will be implanted with PMA P150009 AngelMed Guardian® System and enrolled in the PAS, for the purpose of accruing 314 adjudicated True Positive (TP) or False Positive (FP) ACS events.

Interventions

PMA P150009 AngelMed Guardian® System

The AngelMed Guardian® System is an implantable cardiac monitor with patient alerting capability and an additional external alarm device. The Guardian® System is indicated for use in patients who have had prior ACS events and who remain at high risk for recurrent ACS events. The Guardian® System is indicated as an adjunct to patient recognized symptoms. The Guardian® System detects potential ongoing ACS events, characterized by sustained ST segment changes, and alerts the patient to seek medical attention for those potential ACS events.

A Guardian® System alert is a more accurate predictor of ACS events when compared to patient recognized symptoms alone and demonstrates a reduced rate over time of patient presentations without ACS events (false positives) when compared to patient recognized symptoms alone. In the absence of symptoms, the Guardian® System may identify asymptomatic ACS events and prompt the patient to seek medical attention.

Primary outcome measure

  • Efficacy (PPV and FPR) [ Time Frame: The PAS is a 3 year, event based study, looking to accumulate 314 ACS events. Patients will be seen for an in-office initial programming visit 7-14 days following implant and every 6 months thereafter until study exit or study completion. ]

Central Contacts and Locations

Central contacts

Locations

Phoenix Heart

Recruiting

Glendale, Arizona, United States, 85306

Contacts

Principal Investigator:

Andrew Kaplan, MD

Arizona Heart & Vascular Clinic

Recruiting

Glendale, Arizona, United States, 85308

Contacts

Principal Investigator:

Rahul Malhotra, MD

East Los Angeles Cardiology

Recruiting

Los Angeles, California, United States, 90033

Contacts

Principal Investigator:

Suresh Rao, MD

Clermont Ambulatory Surgical Center

Recruiting

Clermont, Florida, United States, 34711

Contacts

Principal Investigator:

Usman Siddiqui, MD

Daytona Heart Group

Recruiting

Daytona Beach, Florida, United States, 32114

Contacts

Principal Investigator:

Glenn Rayos, MD

Florida Heart Rhythm Specialists

Recruiting

Fort Lauderdale, Florida, United States, 33308

Contacts

Principal Investigator:

David Kenigsberg, MD

Institute for Cardiovascular Research Studies, Inc.

Recruiting

Miami, Florida, United States, 33176

Contacts

Principal Investigator:

Efrain Gonzalez, MD

Northside Hospital Cardiovascular Institute

Recruiting

Atlanta, Georgia, United States, 30342

Contacts

Principal Investigator:

Cindy Grines, MD

Heart Clinic of Hammond

Recruiting

Hammond, Louisiana, United States, 70403

Contacts

Principal Investigator:

Karla Gorio, PA

South Oklahoma Heart Research

Recruiting

Oklahoma City, Oklahoma, United States, 73135

Contacts

Principal Investigator:

Asim Chohan, MD

Texan Cardiovascular Institute

Recruiting

El Paso, Texas, United States, 79915

Contacts

Principal Investigator:

Ali Nasur, MD

Medical City Hospital Forth Worth

Recruiting

Fort Worth, Texas, United States, 76104

Contacts

Principal Investigator:

Amir Malik, MD

More Information

Sponsor

Angel Medical Systems

Last update posted

Sep 30, 2025

Last verified

Sep, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Angel Medical Systems on 2025-09-30.